EL7.AI
StocksMedium•19 November 2026•
4 min read

SELLAS Prices $150 Million Public Offering at $13 per Share

Key Facts

1SELLAS priced the offering at $13.00 per share, with closing expected on November 20, 2026.
2The underwriters’ option allows them to purchase up to 1,730,769 additional shares within 30 days at the same price.
3GPS was associated with a reported 41% reduction in the risk of death and median overall survival of 24.0 months, compared with 14.7 months.
4Research and development expenses totaled $18.430 million in the nine months ended September 30, 2026, compared with $11.292 million a year earlier.
5SELLAS reported a net loss of $28.103 million in the first nine months of 2026, compared with $19.205 million in the corresponding period.

SELLAS Life Sciences priced an underwritten public offering with an aggregate announced value of $150 million on November 19, 2026, setting the price at $13.00 per share, according to a company statement. The company expected the offering to close on November 20, subject to customary closing conditions. It also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares at the same price. The offering is a financing step following the company’s announcement of positive Phase 3 REGAL trial results. SELLAS said net proceeds would be allocated to developing GPS and SLS009, as well as working capital and general corporate purposes.

REGAL results announced by SELLAS on November 17, 2026, show that the GPS vaccine was associated with a reported 41% reduction in the risk of death among trial participants. Median overall survival was 24.0 months with GPS, compared with 14.7 months with best available therapy. The company reported a hazard ratio of 0.59 and a p-value of 0.035, describing the result as statistically significant. The results put the GPS program at the forefront of the offering’s clinical context, while the announced use of proceeds also includes developing SLS009. The announced financing terms do not specify how much will be allocated to each program individually.

On the operational side, SELLAS named J.P. Morgan and TD Cowen as joint book-running managers for the proposed offering, according to the company statement. The book runners coordinate the offering with investors as part of the underwriting arrangements. Their mandate includes a 30-day option to purchase additional shares, up to a maximum of 1,730,769 shares at $13.00 per share. The transaction was expected to close on November 20, 2026, subject to customary closing conditions. These terms allow the company to raise additional financing through the option if the underwriters decide to exercise it, without indicating that the additional shares have already been sold.

The financing plan comes as research and development expenses totaled $18.430 million in the nine months ended September 30, 2026, up from $11.292 million in the same period of 2025, according to the quarterly report filed with the U.S. Securities and Exchange Commission. In the same period, the net loss was $28.103 million, compared with $19.205 million a year earlier. Basic and diluted loss per share was $0.15, versus $0.20 in the comparable nine months of 2025. These figures place clinical development among the company’s rising expense items, while the company said net proceeds from the offering would include funding for the development of GPS and SLS009. The company did not specify in the pricing statement how much would go to research and development or working capital.

SLS shares moved in the sessions preceding the pricing announcement, closing at $19.15 on November 17 and then at $17.95 on November 18, according to EL7 data. The November 18 close was below the prior session’s close, as the market absorbed company news related to the stock offering and REGAL results. Opening prices and intraday highs and lows are not available in the session data used here, so the share-price context is limited to the recorded closing prices. The stock also closed at $7.47 on November 16, before closing at $19.15 on November 17. These prices preceded the company’s November 19 announcement that it had priced the offering at $13.00 per share.

Alongside clinical development, SELLAS said it plans to meet with the U.S. Food and Drug Administration as it continues preparing to submit a biologics license application for GPS. The regulatory path puts the vaccine program at a stage where the company is preparing to discuss next steps with the U.S. agency, according to its announcement of the REGAL results. The near-term financing step is the offering’s expected close on November 20, 2026, subject to customary closing conditions. The option to purchase additional shares remains available to the underwriters for 30 days under the announced pricing terms. The results statement did not give a specific date for the meeting with the agency or for submitting the license application.

Open on chart